{
    "nct_id": "NCT05423210",
    "official_title": "A Pilot Study to Evaluate the Immunogenic Effects of Window-of-Opportunity Fractionated Stereotactic Radiotherapy Combined with Atezolizumab for Patients with Newly Diagnosed WHO CNS Grade 4 Glioma (Glioblastoma Multiforme)",
    "inclusion_criteria": "* Diagnosis of glioblastoma multiforme WHO Grade IV\n* The patient is a surgical candidate, with the surgical intent for a > 80% resection of the lesion\n* Negative pregnancy test\n* ECOG status <= 2\n* Tumor volume <= 3.5 cm\n* Adequate organ function\n* Negative for infectious disease (human immunodeficiency virus, Hepatitis B Virus, Hepatitis C Virus, tubercolosis)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Presence of leptomeningeal disease, gliomatosis cerebri, multifocal disease, bilateral cerebral hemisphere involvement (\"butterfly\" gliomas)\n* Patients at increased risk of neurologic decompensation\n* Continued use of high dose intravenous or oral corticosteroids, or > 8milligrams per day of systemic dexamethasone\n* Uncontrolled tumor-related pain\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)\n* Uncontrolled or symptomatic hypercalcemia\n* History of autoimmune disease or immune deficiency\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis\n* Significant cardiovascular disease\n* History of other malignancy within 1 year prior to screening\n* Severe infection within 4 weeks prior to initiation of study treatment\n* History of allogeneic stem cell or organ transplant\n* Prior treatment with CD137 agonists or immune checkpoint blockade therapies\n* Treatment with systemic immunostimulatory agents\n* Treatment with systemic immunosuppressive medication",
    "miscellaneous_criteria": ""
}